11.04.26 -- The "Fantasy" On Both Sides Of Feasibility

Oncology trials are more complex than ever. Learn how lean biotech teams can balance speed and risk by making smarter early decisions on study design, trial sites, and patient enrollment.

In this presentation, CRIO founder and co-CEO Raymond Nomizu delves into how sponsors can leverage the electronic source trend among sites through the use of Central eSource.

Transforming passive clinical trial meetings into active catalysts for success, aligning teams and accelerating timelines.

This clip shows why speed alone isn’t enough in clinical trials, stressing the need for thoughtful design, operational alignment, and long‑term reliability when pressure to move fast rises.

In this candid discussion, we cover the disconnect between sponsor-designed data systems and the way source data is actually created, managed, and verified at the site.

While both trial auditing and trial monitoring have the same goal of protecting participant safety and rights, they are two separate yet important pieces of the clinical trial process.

QT strategy decisions affect timelines, cost, and regulatory outcomes. This presentation examines when early QT data can support a waiver, how guidance updates influence study design, and more.

Nick Palumbo explains why sponsors and sites can both bring overly optimistic assumptions to feasibility. Epidemiology may show that patients exist, but protocol requirements and a site’s confidence in its enrollment capabilities can tell a very different story.

Commercial growth brings new PV challenges. Gain practical insights on operating models, technology, governance, and leadership for long-term success.